Physician profile
Eric D Snyder
NPI 1013930718
$3,064.67
in general payments reported to CMS, 2019-2025
20 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $213 · 2021: $379 · 2022: $111 · 2023: $1,882 · 2024: $69.42 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Charitable Contribution: $1,700 · Food and Beverage: $364 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Charitable Contribution | $1,700.04 |
| Food and Beverage | $363.59 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microsurgical Technology, INC. | $1,700.04 | 2023 | |
| Lensar, INC. | $261.31 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $210.98 | 2019-2021 | |
| Rxsight INC | $162.66 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $87.04 | 2019-2025 | Eylea Hd |
| Rayner Intraocular Lenses Limited | $71.33 | 2023-2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Allergan, INC. | $68.02 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $57.78 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $52.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $37.46 | 2019-2022 | |
| Harrow Eye, LLC | $36.96 | 2025 | Triesence |
| Bausch & Lomb Americas INC. | $32.70 | 2022-2023 | Vyzulta |
| Glaukos Corporation | $29.09 | 2022-2025 | Idosetr |
| Johnson & Johnson Surgical Vision, INC. | $24.43 | 2023 | Catalys System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $21.79 | 2025 | Oxervate |
| Biotissue Holdings INC. | $18.37 | 2023 | |
| Abbvie INC. | $16.37 | 2022 | |
| Shire North American Group INC | $13.32 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.